Centaurus Financial Inc. Has $590,000 Holdings in Humana Inc. $HUM

Centaurus Financial Inc. raised its stake in Humana Inc. (NYSE:HUM) by 126.7% in the first quarter, Holdings Channel.com reports. The firm owned 3,400 shares of the insurance provider’s stock after acquiring an additional 1,900 shares during the period. Centaurus Financial Inc.’s holdings in Humana were worth $590,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Montag A & Associates Inc. increased its holdings in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after purchasing an additional 94 shares during the period. CoreCap Advisors LLC lifted its stake in shares of Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after buying an additional 37 shares during the period. Fideuram Asset Management Ireland dac bought a new stake in shares of Humana in the fourth quarter valued at about $27,000. Reflection Asset Management acquired a new stake in Humana during the fourth quarter worth about $29,000. Finally, Larson Financial Group LLC grew its position in Humana by 114.1% during the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock worth $40,000 after buying an additional 81 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have commented on HUM. Raymond James Financial cut Humana from an “outperform” rating to a “market perform” rating in a report on Thursday. Barclays raised their price objective on Humana from $344.00 to $407.00 and gave the stock an “equal weight” rating in a research report on Friday. Jefferies Financial Group upgraded Humana from a “buy” rating to a “buy” rating in a research report on Wednesday, May 20th. Royal Bank Of Canada boosted their price objective on Humana from $246.00 to $415.00 and gave the company a “sector perform” rating in a research report on Thursday, July 9th. Finally, Leerink Partners raised Humana from a “market perform” rating to an “outperform” rating and set a $513.00 target price for the company in a research report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $386.61.

Humana Stock Down 0.6%

HUM opened at $364.54 on Friday. The firm has a market cap of $43.77 billion, a price-to-earnings ratio of 34.49, a PEG ratio of 2.06 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.77 and a current ratio of 1.74. The firm’s 50-day simple moving average is $370.79 and its 200-day simple moving average is $268.37. Humana Inc. has a twelve month low of $163.11 and a twelve month high of $428.88.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.27 by $0.34. The firm had revenue of $40.89 billion during the quarter, compared to the consensus estimate of $40.58 billion. Humana had a net margin of 0.88% and a return on equity of 11.20%. The firm’s quarterly revenue was up 26.2% on a year-over-year basis. During the same period last year, the firm posted $6.27 EPS. Equities research analysts anticipate that Humana Inc. will post 9.08 EPS for the current fiscal year.

Humana News Summary

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Analyst upgrades: Leerink Partners raised Humana from “market perform” to “outperform” and set a $513 price target, implying substantial upside. Bank of America also upgraded the stock to “Buy.” Leerink Partners upgrade Bank of America upgrade
• Positive Sentiment: Second-quarter beat: Humana reported adjusted EPS of $7.61, above the $7.27 consensus estimate, while revenue reached $40.89 billion versus expectations of $40.58 billion. Revenue increased 26.2% year over year, and reported profit was approximately $694 million. Humana second-quarter profit report
• Neutral Sentiment: TD Cowen raised its target from $350 to $370 but maintained a “Hold” rating, indicating only modest expected upside and signaling limited conviction despite the higher valuation estimate. TD Cowen price target update
• Negative Sentiment: Unchanged guidance disappointed investors: Humana affirmed its full-year 2026 adjusted earnings outlook rather than raising it after the quarterly beat. Reports also cited pressure from lower Medicare Advantage quality ratings, tempering optimism about near-term earnings growth. Humana stock and second-quarter outlook
• Negative Sentiment: Medicare Advantage exits: Humana plans to withdraw from additional Medicare Advantage markets and plans in 2027 as it targets a 3% margin. The portfolio reshaping may improve profitability over time, but it could reduce membership and revenue growth in the near term. Humana Medicare Advantage plan exits

Humana Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.